CANAQUEST SIGNS MEDICINAL CANNABIS EDUCATION PARTNERSHIP WITH THE CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE
11. März 2021 09:00 ET
|
CanaQuest Medical Corp
TORONTO, March 11, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
CANAQUEST SIGNS MENTANINE® AND MENTABINOL® PRODUCTION AND DISTRIBUTION AGREEMENT WITH PURCANN PHARMA AND SILICYCLE INC.
02. Februar 2021 09:00 ET
|
CanaQuest Medical Corp
TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
CANAQUEST PRESIDENT INTERVIEWED BY THE WALL STREET ANALYZER
19. Januar 2021 09:00 ET
|
CanaQuest Medical Corp
TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
CANAQUEST ANNOUNCES MENTABINOL® A SCIENTIFIC DISCOVERY, AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCE
03. Dezember 2020 09:00 ET
|
CanaQuest Medical Corp
TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL
17. September 2020 09:00 ET
|
CanaQuest Medical Corp
TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE
14. Juli 2020 11:04 ET
|
CanaQuest Medical Corp
TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing...
CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE
14. Juli 2020 09:00 ET
|
CanaQuest Medical Corp
TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing...
Canaquest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®
06. Februar 2020 09:00 ET
|
CanaQuest Medical Corp
TORONTO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a developer of novel health products utilizing cannabis, hemp, and botanical...
CANAQUEST MEDICAL CORP is the Winner of the Go Global Awards "Business of the Year – Category of Life Science” presented by the International Trade Council
29. Oktober 2019 12:19 ET
|
CanaQuest Medical Corp
Research & development is a primary focus for this medical cannabis company TORONTO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or...
CANAQUEST MEDICAL CORP announces filing of INTERNATIONAL CANNABIS PATENT
17. September 2019 09:00 ET
|
CanaQuest Medical Corp
A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL (“THC”) FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS Research & development a primary focus for this medical...